Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Retained Earnings (2016 - 2025)

Regenxbio has reported Retained Earnings over the past 12 years, most recently at -$1.1 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$1.1 billion for Q4 2025, down 151860.46% from a year ago — trailing twelve months through Dec 2025 was -$1.1 billion (down 151860.46% YoY), and the annual figure for FY2025 was -$1.1 billion, down 151860.46%.
  • Retained Earnings for Q4 2025 was -$1.1 billion at Regenxbio, down from -$1.1 billion in the prior quarter.
  • Over the last five years, Retained Earnings for RGNX hit a ceiling of -$741000.0 in Q4 2024 and a floor of -$1.1 billion in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$250.2 million (2021), compared with a mean of -$365.5 million.
  • Biggest five-year swings in Retained Earnings: plummeted 173200.76% in 2021 and later skyrocketed 99.91% in 2025.
  • Regenxbio's Retained Earnings stood at -$161.2 million in 2021, then skyrocketed by 90.45% to -$15.4 million in 2022, then soared by 71.24% to -$4.4 million in 2023, then skyrocketed by 83.27% to -$741000.0 in 2024, then plummeted by 151860.46% to -$1.1 billion in 2025.
  • The last three reported values for Retained Earnings were -$1.1 billion (Q4 2025), -$1.1 billion (Q3 2025), and -$750000.0 (Q2 2025) per Business Quant data.